Evidence map›Paper›PMID 31548332›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2019

Rhinovirus-Induced SIRT-1 via TLR2 Regulates Subsequent Type I and Type III IFN Responses in Airway Epithelial Cells.

Nathaniel Xander, Hymavathi Reddy Vari, Rewees Eskandar, Wuyan Li, Sudhir Bolla, Nathaniel Marchetti, Umadevi S Sajjan

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. ACS omega · 2023
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. NADFrontiers in molecular biosciences · 2021
    Review
  12. Review
  13. Rhinovirus and Innate Immune Function of Airway Epithelium.Frontiers in cellular and infection microbiology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Nathaniel XanderDepartment of Thoracic Surgery and Medicine, Temple University, Philadelphia, PA 19140; and.ORCID 0000-0002-6499-5970
Hymavathi Reddy VariDepartment of Thoracic Surgery and Medicine, Temple University, Philadelphia, PA 19140; and.
Rewees EskandarDepartment of Thoracic Surgery and Medicine, Temple University, Philadelphia, PA 19140; and.
Wuyan LiDepartment of Thoracic Surgery and Medicine, Temple University, Philadelphia, PA 19140; and.ORCID 0000-0002-7208-4456
Sudhir BollaDepartment of Thoracic Surgery and Medicine, Temple University, Philadelphia, PA 19140; and.
Nathaniel MarchettiDepartment of Thoracic Surgery and Medicine, Temple University, Philadelphia, PA 19140; and.
Umadevi S SajjanDepartment of Thoracic Surgery and Medicine, Temple University, Philadelphia, PA 19140; and uma.sajjan@temple.edu.
Temple University · US

Funding

Quercetin prevents progression of COPD lung disease by modulating Foxo3AactivityR01AT007620 · NCCIH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SAJJAN, UMADEVI SIVANAPPA · 2014 to 2018
$2.0M
Co-infections of rhinovirus and bacteria in chronic lung disordersR21HL089772 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SAJJAN, UMADEVI SIVANAPPA · 2009 to 2010
$423k
NCCIH NIH HHS R01 AT007620NHLBI NIH HHS R21 HL089772
6 · The paper itself

Abstract

IFN responses to viral infection are necessary to establish intrinsic antiviral state, but if unchecked can lead to heightened inflammation. Recently, we showed that TLR2 activation contributes to limitation of rhinovirus (RV)-induced IFN response in the airway epithelial cells. We also demonstrated that compared with normal airway epithelial cells, those from patients with chronic obstructive pulmonary disease (COPD) show higher IFN responses to RV, but the underlying mechanisms are not known. Initially, RV-induced IFN responses depend on dsRNA receptor activation and then are amplified via IFN-stimulated activation of JAK/STAT signaling. In this study, we show that in normal cells, TLR2 limits RV-induced IFN responses by attenuating STAT1 and STAT2 phosphorylation and this was associated with TLR2-dependent SIRT-1 expression. Further, inhibition of SIRT-1 enhanced RV-induced IFN responses, and this was accompanied by increased STAT1/STAT2 phosphorylation, indicating that TLR2 may limit RV-induced IFN responses via SIRT-1. COPD airway epithelial cells showed attenuated IL-8 responses to TLR2 agonist despite expressing TLR2 similar to normal, indicating dysregulation in TLR2 signaling pathway. Unlike normal, COPD cells failed to show RV-induced TLR2-dependent SIRT-1 expression. Pretreatment with quercetin, which increases SIRT-1 expression, normalized RV-induced IFN levels in COPD airway epithelial cells. Inhibition of SIRT-1 in quercetin-pretreated COPD cells abolished the normalizing effects of quercetin on RV-induced IFN expression in these cells, confirming that quercetin exerts its effect via SIRT-1. In summary, we show that TLR2 is required for limiting RV-induced IFNs, and this pathway is dysregulated in COPD airway epithelial cells, leading to exaggerated IFN production.

Indexed as

BronchiCells, CulturedEpithelial CellsHumansInterferon-Induced Helicase, IFIH1InterferonsPulmonary Disease, Chronic ObstructiveRhinovirusRNA, Double-StrandedSignal TransductionSirtuin 1STAT Transcription FactorsSuppressor of Cytokine Signaling 1 ProteinToll-Like Receptor 2IFIH1 protein, humanInterferon-Induced Helicase, IFIH1InterferonsRNA, Double-StrandedSIRT1 protein, humanSirtuin 1SOCS1 protein, humanSTAT Transcription FactorsSuppressor of Cytokine Signaling 1 ProteinTLR2 protein, humanToll-Like Receptor 2

Identifiers

PMID31548332
PMCPMC6810856
OpenAlexW2975520635

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.